Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease. Theranostics 2021, Vol. 11, Issue 13

The increase in butyrylcholinesterase (BChE) activity in the brain of Alzheimer disease (AD) patients and animal models of AD position. This enzyme as a potential biomarker of the disease. However, the information on the ability of BChE to serve as AD biomarker is contradicting, also due to scarce longitudinal studies of BChE activity abundance. Here, we report 11C-labeling, in vivo stability, biodistribution, and longitudinal study on BChE abundance in the brains of control and 5xFAD (AD model) animals, using a potent BChE selective inhibitor, and positron emission tomography (PET) in combination with computerised tomography (CT). We correlate the results with in vivo amyloid beta (Aβ) deposition, longitudinally assessed by florbetaben-PET imaging.

Comment on this FAQ

Your email address will not be published. Required fields are marked *

Información básica sobre protección de datos Ver más

  • Responsable El titular del sitio.
  • Finalidad Moderar los comentarios. Responder las consultas.
  • Legitimación Tu consentimiento.
  • Destinatarios .
  • Derechos Acceder, rectificar y suprimir los datos.